Sugi Predict

Sugi Predict / Compounds / SCHEMBL2727403

SCHEMBL2727403

SCHEMBL2727403

CC(C)(C)OC(=O)NC(Cc1c[nH]c2ccccc12)C(N)=O

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 4/20 0.71
▸ CTSS P25774 1/20 0.71
▸ CTSK P43235 1/20 0.71
▸ TACR1 P25103 2/20 0.68
▸ MAPT P10636 2/20 0.67
▸ TP53 P04637 1/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.65
▸ ACE P12821 1/20 0.64
▸ ECE1 P42892 2/20 0.61
▸ CCKBR P32239 3/20 0.60
▸ SSTR3 P32745 1/20 0.60
▸ SCN9A Q15858 1/20 0.58
▸ P4HB P07237 1/20 0.58
▸ GAA P10253 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2727405 1.00 CTSL (0.71) CTSLCTSSCTSKTACR1MAPT
SCHEMBL7413708 1.00 CTSL (0.71) CTSLCTSSCTSKTACR1MAPT
SCHEMBL12267036 0.92 CTSL (0.72) CTSLCTSSCTSKTACR1MAPT
SCHEMBL4849843 0.92 CTSL (0.72) CTSLCTSSCTSKTACR1MAPT
SCHEMBL15586960 0.91 CTSL (0.68) CTSLCTSSCTSKTACR1MAPT
SCHEMBL22133112 0.91 CCKBR (0.73) CTSLCTSSCTSKMAPTTP53
SCHEMBL1486167 0.90 ACE (0.77) CTSLCTSSCTSKTACR1MAPT
SCHEMBL29367687 0.90 ACE (0.77) CTSLCTSSCTSKTACR1MAPT
SCHEMBL30976323 0.90 ACE (0.77) CTSLCTSSCTSKTACR1MAPT
SCHEMBL1003555 0.90 ACE (0.77) CTSLCTSSCTSKTACR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193035-A1 INDOLE COMPOUNDS FOR USE IN NEURORESTORATION GALIMEDIX THERAPEUTICS, INC. (US) 2022-06-23 — — US disclosed
EP-3613420-B1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA INC (US) 2022-05-25 — — EP disclosed
EP-3324958-B1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA INC (US) 2021-07-28 — — EP disclosed
US-9902688-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2018-02-27 — — US disclosed
EP-3176154-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2017-06-07 — — EP disclosed
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2016-11-03 — — US disclosed
US-9359375-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-9284309-B2 Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation NEUROPORE THERAPIES, INC. (US) 2016-03-15 — — US disclosed
US-20150183776-A1 DI- AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION NEUROPORE THERAPIES, INC. (US) 2015-07-02 — — US disclosed
US-20150183776-A1 DI- AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION NEUROPORE THERAPIES, INC. (US) 2015-07-02 — — US disclosed
WO-2014014937-A1 DI-AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION NEUROPORE THERAPIES, INC. (US) 2014-01-23 — — WO disclosed
EP-2635556-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 — — EP disclosed
US-20130012514-A1 AMINOALKYLOXAZOLE AND AMINOALKYLTHIAZOLECARBOXYLIC ACID AMIDES AS REGENERATION-PROMOTING SUBSTANCES FOR SENSORY ORGANS AND POST-MITOTIC TISSUE EMC MICROCOLLECTIONS GMBH (DE) 2013-01-10 — — US disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 — — US disclosed
WO-2012061418-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO disclosed
WO-2011095338-A1 NOVEL AMINOALKYL-OXAZOLE AND AMINOALKYL-THIAZOLE CARBOXYLIC ACID AMIDES AS REGENERATION-PROMOTING SUBSTANCES FOR SENSORY ORGANS AND POST-MITOTIC TISSUE EMC MICROCOLLECTIONS GMBH (DE) 2011-08-11 — — WO disclosed
EP-2298790-A1 Daptomycin analogs as antibacterial agents Cubist Pharmaceuticals, Inc. (US) 2011-03-23 — — EP disclosed
EP-2295444-A2 Lipopeptides as antibacterial agents Cubist Pharmaceutical Inc. (US) 2011-03-16 — — EP disclosed
CN-101970015-A N-alkoxyamide conjugates as imaging agents LANTHEUS MEDICAL IMAGING INC 2011-02-09 — — CN disclosed
US-5554627-A Tachykinin antagonists MERCK, SHARP & DOHME LTD. (GB) 1996-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150183776-A1 DI- AND TRI-HETEROARYL DERIVATIVES AS INHIBITORS OF PROTEIN AGGREGATION PARK7, SNCA, HTT CTSL 3420/4885CTSS 1097/4885CTSK 2151/4885
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK CTSL 1801/4885CTSS 1406/4885CTSK 1202/4885
US-20220193035-A1 INDOLE COMPOUNDS FOR USE IN NEURORESTORATION AANAT, INMT, TPH2 CTSL 2044/4885CTSS 1083/4885CTSK 896/4885
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK CTSL 1801/4885CTSS 1406/4885CTSK 1202/4885
US-20130012514-A1 AMINOALKYLOXAZOLE AND AMINOALKYLTHIAZOLECARBOXYLIC ACID AMIDES AS REGENERATION-PROMOTING SUBSTANCES FOR SENSORY ORGANS AND POST-MITOTIC TISSUE DCX, CCNY, CCNB3 CTSL 874/4885CTSS 1269/4885CTSK 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.